思路迪医药股份(01244)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01244 思路迪医药股份

未开盘 08-20 16:09:07

3.420

+1.240

+56.88%

最高5.000	最低2.675	成交量397.30万
今开2.675	昨收2.180	日振幅106.65%
总市值8.82亿	流通市值8.82亿	总股本2.58亿
成交额1,394万	换手率1.54%	流通股本2.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01244","market":"HK","secType":"STK","nameCN":"思路迪医药股份","latestPrice":3.42,"timestamp":1787213347624,"preClose":2.18,"halted":0,"volume":3973000,"delay":0,"changeRate":0.5688073394495411,"floatShares":258000000,"shares":258000000,"eps":-0.8396018917201948,"marketStatus":"未开盘","change":1.24,"latestTime":"08-20 16:09:07","open":2.675,"high":5,"low":2.675,"amount":13940300,"amplitude":1.066514,"askPrice":3.45,"askSize":21000,"bidPrice":3.42,"bidSize":15000,"shortable":0,"etf":0,"ttmEps":-0.887412554998706,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787275800000},"marketStatusCode":0,"adr":0,"listingDate":1671033600000,"exchange":"SEHK","adjPreClose":2.18,"openAndCloseTimeList":[[1787189400000,1787198400000],[1787202000000,1787212800000]],"volumeRatio":17.610815593469425,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01244","defaultTab":"news","newsList":[{"id":"2660702934","title":"思路迪医药股份午前涨超55% 公司在肿瘤赛道布局瞄准国际最前沿方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2660702934","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660702934?lang=zh_cn&edition=full","pubTime":"2026-08-20 11:39","pubTimestamp":1787197140,"startTime":"0","endTime":"0","summary":"模拟交易客户端思路迪医药股份盘初快速飙升，涨幅一度接近130%，截至发稿，股价上涨55.05%，现报3.38港元，成交额874.42万港元。公开资料显示，思路迪医药在肿瘤赛道布局已久，从全球第一款皮下注射PDL1到全球第一款WT1肿瘤疫苗，自建LNP递送系统和AI-肿瘤疫苗筛选平台，In-vivo Car T/NK等都瞄准国际最前沿方向，与全球顶尖肿瘤免疫赛道形成同频共振。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-20/doc-ininxqxt6779426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","01244"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660706724","title":"港股异动 | 思路迪医药股份(01244.HK)早盘飙升130% 肿瘤免疫治疗迎来里程碑 公司在肿瘤赛道布局瞄准国际最前沿方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2660706724","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660706724?lang=zh_cn&edition=full","pubTime":"2026-08-20 10:51","pubTimestamp":1787194290,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01244"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124447538","title":"港股生物科技股大涨，思路迪医药股份涨超80%，云顶新耀涨超60%","url":"https://stock-news.laohu8.com/highlight/detail?id=1124447538","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124447538?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:30","pubTimestamp":1787189405,"startTime":"0","endTime":"0","summary":"8月20日，港股$生物(000504)$科技股大涨，$思路迪医药股份(01244)$涨超80%，$云顶新耀(01952)$涨超60%，$康希诺生物(06185)$涨超50%，$艾美疫苗(06660)$涨超45%，$剂泰科技-P(07666)$涨超25%，$科济药业-B(02171)$涨超7%。","market":"hk","thumbnail":"https://static.tigerbbs.com/424a61980d8d04f8172cdf5eafb309c0","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/424a61980d8d04f8172cdf5eafb309c0"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","09086","07266","03069","01952","07568","VGT","KCAI","02834","VXUS","03034","BK1161","03455","09834","BK1585","BK1583","06185","07666","07261","BK4588","BK1574","02171","BK1191","BK4585","06660","TTTN","03086","BK1147","BK1515","07522","01244","XLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660479489","title":"港股概念追踪|Moderna股价飙升  肿瘤免疫与mRNA技术迎来价值重估（附概念股）","url":"https://stock-news.laohu8.com/highlight/detail?id=2660479489","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660479489?lang=zh_cn&edition=full","pubTime":"2026-08-20 07:28","pubTimestamp":1787182095,"startTime":"0","endTime":"0","summary":"北京时间8月20日，纳斯达克生物科技指数大涨6.39%，创下六年来最大涨幅；Moderna飙升176.97%，市值增加440亿美元；默沙东收涨12.6%，创2009年3月以来最大单日涨幅。智通财经APP获悉，Moderna与默沙东宣布其联合开发的黑色素瘤mRNA癌症疫苗在III期临床中达到主要终点，这一里程碑事件直接引爆了全球医药板块。Moderna的突破验证了mRNA技术在肿瘤治疗领域的商业化潜力，直接提振了整个生物医药赛道的信心。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482332.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","IE00B0JY6N72.USD","LU0417516738.SGD","LU0348825331.USD","BK4585","LU0708995583.HKD","BK1589","LU0359201612.USD","LU0140636845.USD","LU0516422366.SGD","LU0823426308.USD","BK1610","LU0326950275.SGD","LU0327786744.USD","LU0588546209.SGD","LU1880383366.USD","LU0456827905.SGD","LU0052750758.USD","BK1521","LU3063872942.SGD","VXUS","KURE","LU0516422952.EUR","LU0043850808.USD","02269","SG9999002562.SGD","LU0516423174.USD","LU0572944931.SGD","BK1161","LU0051755006.USD","BK1576","LU0979878070.USD","LU0029874061.USD","LU1688375341.USD","LU0181495838.USD","LU0516422440.USD","LU0819121731.USD","WDNA","LU0348735423.USD","LU0307460666.USD","KCAI","LU2039709279.SGD","SG9999002463.SGD","LU1794554557.SGD","LU0856984785.SGD","LU1242518931.SGD","LU0456846285.SGD","01244","LU0128526141.USD","LU0359202008.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660429689","title":"全球首款mRNA肿瘤疫苗三期达标 思路迪医药(01244)涨17%对标国际获重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2660429689","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660429689?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:16","pubTimestamp":1787148979,"startTime":"0","endTime":"0","summary":"Moderna与默沙东宣布肿瘤新抗原mRNA疫苗mRNA-4157+K药联合辅助治疗黑色素瘤的三期临床INTerpath-001达到主要终点RFS和关键次要终点DMFS。在港股市场，思路迪医药今日收报2.18港元，大涨17.2%，成为板块情绪的核心受益标的之一。在全球肿瘤免疫治疗迈入基因治疗新纪元的当下，思路迪医药凭借差异化的管线布局与商业化节奏，有望持续获得估值重估的催化剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482276.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","159646","BK1574","09939","BK1161","BK1515","01244"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660484451","title":"思路迪医药股份(01244)：已全额收讫SELLAS承担公司产生的相关开支合计798.3万港币","url":"https://stock-news.laohu8.com/highlight/detail?id=2660484451","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660484451?lang=zh_cn&edition=full","pubTime":"2026-08-18 12:47","pubTimestamp":1787028420,"startTime":"0","endTime":"0","summary":"智通财经APP讯，思路迪医药股份(01244)发布公告，内容有关公司与SELLAS Life Sciences Group, Inc. (SELLAS)相关争议案件最新进展所发布的公告。独任仲裁员作出最终裁决，全面驳回SELLAS提出的所有仲裁主张，同时裁定SELLAS须承担公司本次仲裁产生的相关开支合计798.3万港币。公司董事会欣然宣布，公司已全额收讫上述款项，本次仲裁裁决款项已足额执行完毕。本次仲裁仅解决双方历史争议，并作出具有最终效力且具约束力的裁决，不会影响许可协议的效力及后续履行。截至目前，3D189全球多中心临床试验(MRCT)已累计完成78例事件，目标终点为80例事件。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481233.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01244","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165250751","title":"思路迪医药（01244.HK）完成近800万港元仲裁裁决款项收取","url":"https://stock-news.laohu8.com/highlight/detail?id=1165250751","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165250751?lang=zh_cn&edition=full","pubTime":"2026-08-18 12:25","pubTimestamp":1787027147,"startTime":"0","endTime":"0","summary":"2026年8月18日，思路迪医药股份有限公司发布自愿公告称，公司已全额收取与SELLAS Life Sciences Group, Inc.仲裁相关的裁决款项，共计7,983,004.42港币。公告回溯显示，2026年7月27日独任仲裁员就双方争议作出最终裁决：驳回SELLAS全部仲裁主张，并裁定SELLAS承担思路迪医药在本案中产生的全部费用7,983,004.42港币。思路迪医药表示，发布本公告旨在向股东及潜在投资者通报最新业务进展，并提醒投资者在买卖公司证券时保持审慎。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01244"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127782129","title":"思路迪医药股份（01244）将于8月31日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1127782129","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127782129?lang=zh_cn&edition=full","pubTime":"2026-08-17 21:31","pubTimestamp":1786973485,"startTime":"0","endTime":"0","summary":"思路迪医药股份（01244）8月17日公告，公司董事会拟于2026年8月31日（星期一）召开会议，主要议程包括：  \n1. 审议截至2026年6月30日止六个月未经审核的中期业绩；  \n2. 考虑派发中期股息（如有）。\n公告显示，董事会成员包括执行董事龚兆龙博士，非执行董事张文华女士、周峰先生及陈雅雯女士，以及独立非执行董事李靖博士、连达鹏博士和刘信光先生。\n公司将于董事会会议后发布相关业绩公告。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01244"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659299118","title":"创新药概念集体回调 康方生物（09926）跌6.85%、维亚生物（01873）跌6.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659299118","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659299118?lang=zh_cn&edition=full","pubTime":"2026-08-14 13:51","pubTimestamp":1786686711,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念集体回调，康方生物 跌6.85%，维亚生物跌6.33%，思路迪医药股份跌6.15%，恒瑞医药跌5.10%，晶泰控股跌4.88%，凯莱英跌4.67%，亚盛医药跌4.04%，药明康德跌3.94%，百济神州跌3.92%。西南证券表示，CXO+创新药放量领涨，8-9月有望迎来业绩+临床数据共振。从产业链的角度，CXO板块投融资改善明显，26H1中国/全球医疗健康投融资分别676.47亿元/2416.43亿元，ADC、多肽、细胞基因治疗等新药物形式赛道持续火热，头部CXO公司海外订单复苏明显。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988233","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0572944931.SGD","01276","LU1770034418.SGD","LU2476274720.SGD","159992","LU0359202008.SGD","BK1574","LU0307460666.USD","LU0348827113.USD","02228","06821","IBBQ","LU2045819591.USD","01244","LU0052750758.USD","LU1720050803.USD","BK1576","02359","LU2242644610.SGD","06855","LNGR","LU1794554557.SGD","01873","BK1617","LU0327786744.USD","LU0634319403.HKD","LU0588546209.SGD","IE00B5MMRT66.SGD","LU0348766576.USD","LU0348784397.USD","LU1251922891.USD","KURE","LU2476274308.USD","LU0228659784.USD","LU2778985437.USD","LU1961090484.USD","IE00B543WZ88.USD","BK1588","LU0828237510.HKD","LU2399975544.HKD","LU0348783233.USD","BK1141","LU0708995583.HKD","06160","MEDX","06978","LU1719994722.HKD","LU0359201612.USD","LU0561508036.HKD","09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195583653","title":"思路迪医药（01244）公布最新董事会及三大委员会构成","url":"https://stock-news.laohu8.com/highlight/detail?id=1195583653","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195583653?lang=zh_cn&edition=full","pubTime":"2026-08-07 22:31","pubTimestamp":1786113068,"startTime":"0","endTime":"0","summary":"2026年8月7日，思路迪医药股份有限公司在港交所披露董事名单及其角色与职能，并公布董事会下设三大委员会最新成员组成。上述任命即时生效。公告显示，思路迪医药董事会现由7名董事构成，其中独立非执行董事占比约43%，符合上市规则对独立性及公司治理结构的要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01244"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197025949","title":"思路迪医药（01244）董事会调整：朱晋桥辞任，张文华获委任为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=1197025949","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197025949?lang=zh_cn&edition=full","pubTime":"2026-08-07 22:22","pubTimestamp":1786112536,"startTime":"0","endTime":"0","summary":"2026年8月7日，思路迪医药股份有限公司公告称，公司董事会已收到朱晋桥先生的辞呈，其非执行董事职务自即日起生效。朱晋桥先生因投身个人事务及发展需要提出辞任，并确认与董事会无意见分歧，亦无其他应提请股东注意的事项。同日，董事会任命张文华女士为非执行董事，任期自2026年8月7日起，为期一年，并将在下一届股东周年大会届满退任并可按公司章程细则续任。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01244"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657644565","title":"思路迪医药股份(01244)：张文华获任命为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2657644565","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657644565?lang=zh_cn&edition=full","pubTime":"2026-08-07 22:20","pubTimestamp":1786112407,"startTime":"0","endTime":"0","summary":"智通财经APP讯，思路迪医药股份(01244)发布公告，朱晋桥先生已辞任非执行董事，自2026年8月7日起生效，以便投入更多时间于其个人事务及发展。朱晋桥先生退任后，董事会任命张文华女士为非执行董事，自2026年8月7起生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477602.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01244","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139051446","title":"思路迪医药股份2026年7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1139051446","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139051446?lang=zh_cn&edition=full","pubTime":"2026-08-06 15:46","pubTimestamp":1786002373,"startTime":"0","endTime":"0","summary":"思路迪医药股份有限公司于2026年8月6日发布2026年7月股份变动月报表，报告期截至2026年7月31日。根据公告，公司法定注册股本维持在500,000股，对应注册股本总额为港币500,000元。报告期内，已发行普通股为258,177,000股，较上月底无变动。本月公司无新增发行、购回或注销股份，库藏股数量为0；共计已发行及流通在外股份总数维持在258,177,000股不变。本次公告由董事龚兆龙签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01244"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104215996","title":"思路迪医药股份7月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1104215996","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104215996?lang=zh_cn&edition=full","pubTime":"2026-08-06 10:20","pubTimestamp":1785982845,"startTime":"0","endTime":"0","summary":"思路迪医药股份有限公司于2026年8月6日发布截至2026年7月31日的月度股份变动报告。报告显示，公司注册股本为500,000港元，期末仍维持该规模未发生任何增减变动。根据报告，思路迪医药股份于7月末的已发行股份总数为258,177,000股，均为普通股，较上月底保持不变，且无持作库藏的股份。此外，公司符合香港联交所关于最低公众持股量的相关要求。公司声明所有股票发行及库藏股份变动均已获得董事会正式授权，符合上市规则及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01244"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191994440","title":"思路迪医药股份（01244）调整法律程序文件代理人与香港主要营业地点","url":"https://stock-news.laohu8.com/highlight/detail?id=1191994440","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191994440?lang=zh_cn&edition=full","pubTime":"2026-08-04 22:15","pubTimestamp":1785852941,"startTime":"0","endTime":"0","summary":"思路迪医药股份（01244）8月4日在港交所发布公告称，公司董事会根据《公司条例》（香港法例第622章）第16部规定，委任梁晶晶女士自2026年8月4日起出任公司在香港接收法律程序及通知的代理人，接替李菁怡女士。\n公告同时披露，公司自2026年8月4日起将香港主要营业地点由原址迁往香港干诺道中111号永安中心16楼。\n据公告，截至本公告日期，公司董事会成员包括：执行董事龚兆龙博士；非执行董事朱晋桥先生、周峰先生及陈雅雯女士；独立非执行董事李靖博士、连达鹏博士及刘信光先生。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01244"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656216554","title":"思路迪医药股份(01244)：梁晶晶获委任为法律程序文件代理人","url":"https://stock-news.laohu8.com/highlight/detail?id=2656216554","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656216554?lang=zh_cn&edition=full","pubTime":"2026-08-04 22:11","pubTimestamp":1785852719,"startTime":"0","endTime":"0","summary":"智通财经APP讯，思路迪医药股份(01244)发布公告，梁晶晶女士获委任接替李菁怡女士出任代表公司于香港接收法律程序及通知的代理人(法律程序文件代理人)，自2026年8月4日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1476011.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01244"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655385867","title":"思路迪医药(01244)公告仲裁利好：全面胜诉SELLAS持续推进3D189大中华区开发与商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2655385867","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655385867?lang=zh_cn&edition=full","pubTime":"2026-07-29 11:29","pubTimestamp":1785295750,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，思路迪医药股份发布内幕消息公告，披露公司与SELLAS Life Sciences Group, Inc.相关争议仲裁案件取得重大积极裁决结果。独任仲裁员作出最终裁决，全面驳回SELLAS提出的全部仲裁主张；同时裁定SELLAS承担本次仲裁产生的相关开支，合计7,983,004.42港元。SELLAS须于裁决出具当日起14日内足额支付上述款项；若未能按期足额清偿欠款，未偿付金额将按照年利率8%计收逾期利息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473450.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1574","BK1161","09939","01244","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185070534","title":"SELLAS Life Sciences Group Inc: 思路迪医药将持续推进Galinpepimut-S在大中华区的开发与商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=1185070534","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185070534?lang=zh_cn&edition=full","pubTime":"2026-07-28 04:39","pubTimestamp":1785184749,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences Group Inc宣布，思路迪医药股份（3D Medicines）将继续推进Galinpepimut-S在大中华区的开发与商业化工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK1161","SLS","01244"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654493800","title":"思路迪医药股份(01244)：独任仲裁员裁决全面驳回SELLAS提出的所有仲裁主张","url":"https://stock-news.laohu8.com/highlight/detail?id=2654493800","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654493800?lang=zh_cn&edition=full","pubTime":"2026-07-27 23:02","pubTimestamp":1785164532,"startTime":"0","endTime":"0","summary":"独任仲裁员作出最终裁决，全面驳回SELLAS提出的所有仲裁主张，同时裁定 SELLAS须承担本公司本次仲裁产生的相关开支合计798.3万港币。SELLAS 须于裁决出具当日起计14日内悉数缴付该笔款项;倘其未能按期足额清偿任何欠款，未偿金额将按年利率8%计收逾期利息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472840.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01244"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138082349","title":"思路迪医药（01244）仲裁获判胜诉　SELLAS被裁定支付约7,983万港元费用","url":"https://stock-news.laohu8.com/highlight/detail?id=1138082349","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138082349?lang=zh_cn&edition=full","pubTime":"2026-07-27 23:01","pubTimestamp":1785164466,"startTime":"0","endTime":"0","summary":"思路迪医药股份有限公司7月27日公告称，香港国际仲裁中心已就公司与SELLAS Life Sciences Group, Inc.的争议作出最终裁决。独任仲裁员全面驳回SELLAS提出的所有仲裁主张，并裁定SELLAS须承担本次仲裁的相关开支合计7,983,004.42港币。根据裁决，SELLAS须在裁决出具之日起14日内全额支付上述费用；若逾期未付，未偿金额将按年利率8%计收逾期利息。思路迪医药表示，本次仲裁结果不影响与SELLAS既有的许可协议履行，公司将继续按照协议推进3D189在大中华区的开发及商业化工作。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01244"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.3d-medicines.com","stockEarnings":[{"period":"1week","weight":0.7538},{"period":"1month","weight":0.6056},{"period":"3month","weight":0.0301},{"period":"6month","weight":-0.1186},{"period":"1year","weight":-0.557},{"period":"ytd","weight":-0.3583}],"compareEarnings":[{"period":"1week","weight":0.0119},{"period":"1month","weight":0.0225},{"period":"3month","weight":0.0036},{"period":"6month","weight":-0.0271},{"period":"1year","weight":0.0212},{"period":"ytd","weight":0.0027}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"思路迪医药股份有限公司是一家主要从事生物制药研发及商业化业务的投资控股公司。该公司专注于肿瘤慢病化治疗领域的创新药物发现、开发及商业化，同时布局肿瘤疼痛管理领域。该公司已经构建一套完整的公司内部研发体系，已实现了从药物发现，临床前开发，临床试验、注册的全流程覆盖。该公司第一款上市药物恩维达是一款用于治疗泛瘤种的皮下注射PD-L1抑制剂。该公司还拥有多项创新药研发管线。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.034607},{"month":2,"riseRate":0.75,"avgChangeRate":0.110633},{"month":3,"riseRate":0.25,"avgChangeRate":0.037641},{"month":4,"riseRate":0.25,"avgChangeRate":-0.031877},{"month":5,"riseRate":0.5,"avgChangeRate":0.043316},{"month":6,"riseRate":0.25,"avgChangeRate":-0.039804},{"month":7,"riseRate":0.25,"avgChangeRate":-0.021803},{"month":8,"riseRate":0.5,"avgChangeRate":-0.001038},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.13358},{"month":10,"riseRate":0,"avgChangeRate":-0.260453},{"month":11,"riseRate":0,"avgChangeRate":-0.194469},{"month":12,"riseRate":0.666667,"avgChangeRate":0.250685}],"exchange":"SEHK","name":"思路迪医药股份","nameEN":"3D MEDICINES"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"思路迪医药股份(01244)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供思路迪医药股份(01244)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"思路迪医药股份,01244,思路迪医药股份股票,思路迪医药股份股票老虎,思路迪医药股份股票老虎国际,思路迪医药股份行情,思路迪医药股份股票行情,思路迪医药股份股价,思路迪医药股份股市,思路迪医药股份股票价格,思路迪医药股份股票交易,思路迪医药股份股票购买,思路迪医药股份股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"思路迪医药股份(01244)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供思路迪医药股份(01244)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}